Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Expects US Success For Biosimilar Trastuzumab Despite Amgen Launch

Executive Summary

Leading Indian biologics firm Biocon reported first-quarter net profit soared more than 70% and said it is confident of a “very successful” US biosimilar trastuzumab launch, despite rival Amgen stealing a march by commercializing its own version first in the world’s largest drug market.

You may also be interested in...



Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment

Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.

Mylan-Biocon’s Ogivri First Off Block In Australia But Competition In Sight

Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel